Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Type 1 diabetes mellitus (T1D) arises from selective immunologically mediated destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans with consequent insulin deficiency. This occurs in genetically susceptible individuals and is a cellular-mediated process, presumably a specific reaction to one or more beta-cell proteins (autoantigens), although probably initiated by some environmental factor(s). There is consequent progressive impairment of beta-cell function and decline in beta-cell mass. A secondary humoral immune response is characterized by the appearance of autoantibodies that serve as markers of the immune damage to beta-cells. This insidious T1D disease process evolves over a period of years. The decline in beta-cell function and mass is evidenced metabolically by loss of first-phase insulin response to an intravenous glucose challenge, and later by the appearance of impairment in glycemic regulation, manifested as dysglycemia--usually as impaired glucose tolerance, but occasionally as impaired fasting glucose. Ultimately, the clinical syndrome of T1D becomes evident when the majority of beta-cells have been destroyed and frank hyperglycemia supervenes. Given this sequence of events, for which it is possible to envision intervention to interdict the process, it is not surprising that much research effort has been expended to identify individuals at risk of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Gale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448
Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes
Agardh, C.-D., Cilio, C. M., Lethagen, Å., Lynch, K., Leslie, R. D. G., Palmér, M., Harris, R. A., Robertson, J. A., & Lernmark, Å. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.12.003 · Cited by 226
The Canadian-European Randomized Control Trial Group (1988) · Diabetes · doi:10.2337/diab.37.11.1574 · Cited by 164
Cited by
Engin, F., Yermalovich, A., Nguyen, T., Hummasti, S., Fu, W., Eizirik, D. L., Mathis, D., & Hotamisligil, G. S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006534 · Cited by 318
The Pathogenesis and Natural History of Type 1 Diabetes
Atkinson, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007641 · Cited by 314
Wenzlau, J. M., Liu, Y., Yu, L., Moua, O., Fowler, K. T., Rangasamy, S., Walters, J., Eisenbarth, G. S., Davidson, H. W., & Hutton, J. C. (2008) · Diabetes · doi:10.2337/db08-0522 · Cited by 205
“Given its high tissue specificity, ZnT8 is an attractive candidate as a component of a DNA- or peptide-based vaccine (23,24) to prevent or retard the onset of type 1 diabetes.”
BackgroundSosenko, J. M., Palmer, J. P., Rafkin-Mervis, L., Krischer, J. P., Cuthbertson, D., Mahon, J., Greenbaum, C. J., Cowie, C. C., Skyler, J. S., & the Diabetes Prevention Trial–Type 1 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-2140 · Cited by 76
Self-citationSosenko, J. M., Palmer, J. P., Rafkin, L. E., Krischer, J. P., Cuthbertson, D., Greenbaum, C. J., Eisenbarth, G., Skyler, J. S., & Diabetes Prevention Trial–Type 1 Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1770 · Cited by 62
Self-citation
Metadata
- Authors
- Skyler, J. S.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-03-28
- Volume
- 81
- Issue
- 5
- Pages
- 768-771
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2135251613
- Cited by
- 77
- References
- 8
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects. https://app.cochat.ai/papers/10.1038/sj.clpt.6100179
- The paper
- Skyler, J. S. (2007). Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/sj.clpt.6100179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.